European Commission adds chronic weight management to Mounjaro

The European Commission on December 11, 2023 approved an extension of indication for Mounjaro (tirzepatide) to cover chronic weight management in adults, following a positive opinion from the European Medicines Agency's human medicines committee on November 9, 2023 ^[1]. Rather than launching the weight-loss version under a different trade name, the EU added the new use to the marketing authorization Mounjaro already held for type 2 diabetes ^[1].

The regulatory file, listed as procedure II/0007, describes the new indication as "chronic weight management, including weight loss and weight maintenance" for Mounjaro, used alongside a reduced-calorie diet and increased physical activity, in adults with a starting body mass index of 30 kg/m2 or higher (obesity), or 27 kg/m2 to under 30 kg/m2 (overweight) with at least one weight-related health condition ^[1].

What the evidence showed

The approval was based on the global pivotal phase 3 trial SURMOUNT-1 (study code I8F-MC-GPHK), supported by five phase 3 SURPASS studies (SURPASS-1 through -5) in people with type 2 diabetes and a BMI of 27 kg/m2 or above ^[1]. SURMOUNT-1 was a randomized, double-blind, placebo-controlled trial testing once-weekly tirzepatide in people without type 2 diabetes who had obesity or were overweight with weight-related conditions ^[1].

EMA's public summary describes the weight-management study as involving more than 2,500 participants. After 72 weeks of tirzepatide plus diet and physical activity, average weight reduction was at least 15%, depending on the dose, compared with 3% for placebo ^[2]. More than 85% of participants on tirzepatide lost at least 5% of their body weight, versus 35% on placebo ^[2].

As part of the change, sections 4.1, 4.8, 5.1 and 5.2 of the Summary of Product Characteristics were updated, along with the package leaflet, and version 2.1 of the risk management plan was submitted ^[1]. Those sections cover the approved uses, side effects, and clinical and pharmacokinetic data.

Tirzepatide acts like two gut hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which increase insulin release after eating and also reduce appetite ^[2]. EMA lists the most common side effects — those that may affect more than 1 in 10 people — as low blood glucose (when used with a sulfonylurea or insulin), nausea, vomiting, abdominal pain, constipation and diarrhea ^[2]. The agency has said gut-related side effects were generally mild or moderate and happened more often shortly after a dose increase ^[2].

Mounjaro first received an EU-wide marketing authorization on September 15, 2022, for type 2 diabetes ^[2].

Why it matters for patients

For US readers, this European decision does not change what is sold or covered in the United States; it applies to the EU marketing authorization ^[1]. What it does show is that the same molecule can carry different branding structures in different regions. In the EU, one product name and one label now cover both blood sugar control and weight management ^[1][2]. These sources do not describe how tirzepatide is branded or labeled in the US, so any comparison beyond that is not documented here.

The practical consequence of a single-brand approach is that the EU label, leaflet and safety information are shared across both uses, which can matter for anyone comparing package inserts across countries or trying to make sense of differing product names while traveling. It also means the weight-management data and the diabetes data sit in the same official document ^[1].

What happens next

The EU label has continued to expand. In February 2024, an extension application added six new pen strengths — 2.5, 5, 7.5, 10, 12.5 and 15 mg per dose in the KwikPen multidose pen — with a Commission decision on April 19, 2024 ^[1]. In December 2024, the committee backed adding data from two trials in adults with moderate-to-severe obstructive sleep apnea and obesity, with a Commission decision on February 14, 2025 ^[1]. EMA's current overview lists obstructive sleep apnea among the weight-related health problems that can qualify an overweight adult for treatment ^[2]. A further opinion dated January 29, 2026 covers results from SUMMIT, a trial in heart failure with preserved ejection fraction and obesity ^[1].